Insider Selling: GeneDx Holdings Corp. (NASDAQ:WGS) CFO Sells 3,749 Shares of Stock

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CFO Kevin Feeley sold 3,749 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $96.71, for a total value of $362,565.79. Following the sale, the chief financial officer now owns 8,492 shares of the company's stock, valued at approximately $821,261.32. The trade was a 30.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kevin Feeley also recently made the following trade(s):

• On Thursday, March 13th, Kevin Feeley sold 402 shares of GeneDx stock. The shares were sold at an average price of $90.05, for a total transaction of $36,200.10.
• On Monday, March 10th, Kevin Feeley sold 922 shares of GeneDx stock. The shares were sold at an average price of $94.72, for a total transaction of $87,331.84.
• On Wednesday, January 29th, Kevin Feeley sold 275 shares of GeneDx stock. The stock was sold at an average price of $78.48, for a total value of $21,582.00.
• On Tuesday, January 7th, Kevin Feeley sold 35,506 shares of GeneDx stock. The shares were sold at an average price of $93.82, for a total value of $3,331,172.92.
• On Thursday, January 2nd, Kevin Feeley sold 1,430 shares of GeneDx stock. The stock was sold at an average price of $76.04, for a total transaction of $108,737.20.

GeneDx Trading Up 7.9 %

Shares of WGS traded up $7.68 on Friday, reaching $104.39. 704,762 shares of the company's stock were exchanged, compared to its average volume of 617,273. The business has a 50 day moving average price of $84.59 and a two-hundred day moving average price of $71.15. GeneDx Holdings Corp. has a 12 month low of $8.10 and a 12 month high of $115.60. The stock has a market capitalization of $2.93 billion, a P/E ratio of -53.26 and a beta of 1.91. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

Remove Ads

GeneDx (NASDAQ:WGS - Get Free Report) last issued its earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.04 by $0.66. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. The company had revenue of $95.64 million during the quarter, compared to analysts' expectations of $82.24 million. Research analysts anticipate that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Hedge Funds Weigh In On GeneDx

Institutional investors have recently modified their holdings of the stock. Barclays PLC raised its holdings in GeneDx by 346.3% in the third quarter. Barclays PLC now owns 18,921 shares of the company's stock worth $803,000 after purchasing an additional 14,681 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of GeneDx in the 3rd quarter valued at $325,000. Charles Schwab Investment Management Inc. raised its stake in GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company's stock worth $6,240,000 after buying an additional 110,666 shares during the period. Franklin Resources Inc. bought a new position in GeneDx during the third quarter worth about $301,000. Finally, Principal Financial Group Inc. acquired a new position in GeneDx in the third quarter valued at about $604,000. 61.72% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. TD Cowen raised their target price on GeneDx from $75.00 to $118.00 and gave the stock a "buy" rating in a research report on Tuesday, January 7th. The Goldman Sachs Group upped their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 19th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $72.33.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.